Physix Frontier · News Briefing Card (TMTPost · Nov 8, 2026)

Huawei, OpenAI, ByteDance Accelerate AI Drug Discovery Push

KEY FACTS

In December 2025, Huawei established a pharmaceutical business unit, positioning itself as an AI enabler for the pharma industry, not as a drug developer or pipeline owner.
OpenAI released its life sciences model GPT-Rosalind in April and formed a strategic partnership with Novo Nordisk.
Anthropic acquired AI biotech startup Coefficient Bio, which has fewer than 10 employees, for $400 million.
In June, ByteDance spun off its AI drug discovery business as Anew Labs, which completed a $290 million first funding round three months later.
No drug fully designed by AI has yet completed Phase III clinical trials and received marketing approval anywhere in the world.

KEY DATA

$2.1 billionIsomorphic Labs Series B funding

$40-50 billionIsomorphic Labs valuation

Approximately $1.5 billionAnew Labs post-money valuation

2 to 4 timesAI preclinical R&D efficiency improvement

PHYSIX OBSERVATION

Tech giants are crowding into AI drug discovery, attracted by the pharmaceutical industry's enormous market space and AI's ability to reduce costs and boost efficiency in preclinical stages. However, AI's advantage drops off a cliff in Phase II clinical trials, showing that human biological complexity remains an insurmountable barrier. In the short term, the role of an enabler selling shovels is more realistic than developing drugs oneself, and the industry must be wary of misinterpreting preclinical efficiency gains as a wholesale disruption of the pharmaceutical paradigm.

Source: TMTPost report